{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Influenza+Vaccine+2&page=15", "query": { "intervention": "Influenza Vaccine 2", "page": 15 }, "page_size": 10 }, "pagination": { "page": 15, "page_size": 10, "total_count": 575, "total_pages": 58, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Influenza+Vaccine+2&page=16&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Influenza+Vaccine+2&page=14&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-14T19:29:24.600Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06518577", "title": "Immunogenicity of Influenza Vaccinations", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Influenza" ], "interventions": [ { "name": "Flucelvax® (ccIIV3)", "type": "BIOLOGICAL" }, { "name": "Flublok® (RIV3)", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Duke University", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "64 Years", "sex": "ALL", "summary": "18 Years to 64 Years" }, "enrollment_count": 606, "start_date": "2024-09-09", "completion_date": "2025-06-04", "has_results": true, "last_update_posted_date": "2026-07-28", "last_synced_at": "2026-10-14T19:29:24.600Z", "location_count": 7, "location_summary": "Phoenix, Arizona • Tempe, Arizona • Atlanta, Georgia + 3 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Tempe", "state": "Arizona" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT06518577" }, { "nct_id": "NCT01857206", "title": "Safety of Two Trivalent Influenza Vaccines Evaluated in Children and Adolescents 4 to 17 Years of Age", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Influenza", "Fever" ], "interventions": [ { "name": "Mammalian cell based flu vaccine", "type": "BIOLOGICAL" }, { "name": "Egg based flu vaccine", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Novartis Vaccines", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "4 Years", "maximum_age": "17 Years", "sex": "ALL", "summary": "4 Years to 17 Years" }, "enrollment_count": 2055, "start_date": "2013-05", "completion_date": "2014-06", "has_results": true, "last_update_posted_date": "2014-12-05", "last_synced_at": "2026-10-14T19:29:24.600Z", "location_count": 18, "location_summary": "Mobile, Alabama • Ponte Vedra, Florida • Augusta, Kansas + 12 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Ponte Vedra", "state": "Florida" }, { "city": "Augusta", "state": "Kansas" }, { "city": "Newton", "state": "Kansas" }, { "city": "Wichita", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01857206" }, { "nct_id": "NCT04978454", "title": "Influenza Challenge Study to Determine the Optimal Infection Dose and Safety of a Recombinant H3N2 (A/Texas/71/2017 (H3N2, Clade 3C3a) Influenza Strain", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Influenza" ], "interventions": [ { "name": "Influenza RG-A/Texas/71/2017 (H3N2) Challenge", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "45 Years", "sex": "ALL", "summary": "18 Years to 45 Years" }, "enrollment_count": 60, "start_date": "2021-08-19", "completion_date": "2022-09-22", "has_results": true, "last_update_posted_date": "2025-08-28", "last_synced_at": "2026-10-14T19:29:24.600Z", "location_count": 2, "location_summary": "Baltimore, Maryland • Durham, North Carolina", "locations": [ { "city": "Baltimore", "state": "Maryland" }, { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT04978454" }, { "nct_id": "NCT01924169", "title": "Lenalidomide as Immune Adjuvant in Patient's With Chronic Lymphocytic Leukemia (CLL)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hematologic Disorder" ], "interventions": [ { "name": "Lenalidomide", "type": "DRUG" }, { "name": "Influenza Vaccine", "type": "BIOLOGICAL" }, { "name": "Pneumovax Vaccine", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 3, "start_date": "2014-11-24", "completion_date": "2017-02-21", "has_results": true, "last_update_posted_date": "2018-09-20", "last_synced_at": "2026-10-14T19:29:24.600Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01924169" }, { "nct_id": "NCT07121192", "title": "A Study to Assess the Immune Response and Safety of a Vaccine Against Influenza in Adults 18 Years of Age and Older", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Influenza, Human" ], "interventions": [ { "name": "Flu mRNA (Formulation A)", "type": "BIOLOGICAL" }, { "name": "Flu mRNA (Formulation B)", "type": "BIOLOGICAL" }, { "name": "Comparator 1", "type": "COMBINATION_PRODUCT" }, { "name": "Comparator 2", "type": "COMBINATION_PRODUCT" }, { "name": "Comparator 3", "type": "COMBINATION_PRODUCT" } ], "intervention_types": [ "BIOLOGICAL", "COMBINATION_PRODUCT" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 776, "start_date": "2025-08-25", "completion_date": "2026-05-11", "has_results": false, "last_update_posted_date": "2026-05-28", "last_synced_at": "2026-10-14T19:29:24.600Z", "location_count": 22, "location_summary": "Anniston, Alabama • Fair Oaks, California • San Diego, California + 18 more", "locations": [ { "city": "Anniston", "state": "Alabama" }, { "city": "Fair Oaks", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Walnut Creek", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07121192" }, { "nct_id": "NCT00943631", "title": "Sanofi H1N1 Influenza Vaccine Administered at Two Dose Levels in Adult and Elderly Populations", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Influenza" ], "interventions": [ { "name": "Inactivated H1N1 Vaccine", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 406, "start_date": "2009-08", "completion_date": "2010-03", "has_results": true, "last_update_posted_date": "2012-10-31", "last_synced_at": "2026-10-14T19:29:24.600Z", "location_count": 3, "location_summary": "Baltimore, Maryland • Durham, North Carolina • Nashville, Tennessee", "locations": [ { "city": "Baltimore", "state": "Maryland" }, { "city": "Durham", "state": "North Carolina" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT00943631" }, { "nct_id": "NCT02287467", "title": "Evaluating the Safety and Efficacy of Anti-Influenza Intravenous Hyperimmune Immunoglobulin (IVIG) in Adults Hospitalized With Influenza", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Influenza A", "Influenza B" ], "interventions": [ { "name": "Intravenous hyperimmune immunoglobulin (IVIG)", "type": "BIOLOGICAL" }, { "name": "Placebo for IVIG", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 329, "start_date": "2015-01", "completion_date": "2018-06-07", "has_results": true, "last_update_posted_date": "2019-11-14", "last_synced_at": "2026-10-14T19:29:24.600Z", "location_count": 17, "location_summary": "San Diego, California • Denver, Colorado • Chicago, Illinois + 14 more", "locations": [ { "city": "San Diego", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Bethesda", "state": "Maryland" }, { "city": "Detroit", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT02287467" }, { "nct_id": "NCT01227967", "title": "Comparing the Efficacy, Safety, and Tolerability of Combination Antivirals (Amantadine, Ribavirin, Oseltamivir) Versus Oseltamivir for the Treatment of Influenza in Adults at Risk for Complications", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Influenza" ], "interventions": [ { "name": "Amantadine, Ribavirin, Oseltamivir", "type": "DRUG" }, { "name": "Oseltamivir", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 881, "start_date": "2010-09", "completion_date": "2017-03-30", "has_results": true, "last_update_posted_date": "2019-02-04", "last_synced_at": "2026-10-14T19:29:24.600Z", "location_count": 69, "location_summary": "Birmingham, Alabama • Chandler, Arizona • Glendale, Arizona + 58 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Chandler", "state": "Arizona" }, { "city": "Glendale", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Costa Mesa", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01227967" }, { "nct_id": "NCT02485639", "title": "Analysis of Bone Marrow and Blood B Cell Immune Responses to Influenza Vaccination", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Influenza", "Influenza Immunisation" ], "interventions": [ { "name": "Influenza Virus Vaccine Inactivated", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "49 Years", "sex": "ALL", "summary": "18 Years to 49 Years" }, "enrollment_count": 27, "start_date": "2015-12-23", "completion_date": "2020-03-31", "has_results": true, "last_update_posted_date": "2023-10-24", "last_synced_at": "2026-10-14T19:29:24.600Z", "location_count": 1, "location_summary": "Atlanta, Georgia", "locations": [ { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT02485639" }, { "nct_id": "NCT03658629", "title": "Phase 2 Dose and Formulation Confirmation of Quad-NIV in Older Adults", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Influenza, Human" ], "interventions": [ { "name": "NanoFlu (Quad-NIV)", "type": "BIOLOGICAL" }, { "name": "Matrix-M Adjuvant", "type": "OTHER" }, { "name": "Placebo", "type": "OTHER" }, { "name": "Fluzone HD", "type": "BIOLOGICAL" }, { "name": "Flublok Quadrivalent", "type": "BIOLOGICAL" }, { "name": "Influenza Vaccine", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "Novavax", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "65 Years", "maximum_age": null, "sex": "ALL", "summary": "65 Years and older" }, "enrollment_count": 1375, "start_date": "2018-09-24", "completion_date": "2019-04-26", "has_results": true, "last_update_posted_date": "2022-11-04", "last_synced_at": "2026-10-14T19:29:24.600Z", "location_count": 14, "location_summary": "Hollywood, Florida • Savannah, Georgia • Stockbridge, Georgia + 11 more", "locations": [ { "city": "Hollywood", "state": "Florida" }, { "city": "Savannah", "state": "Georgia" }, { "city": "Stockbridge", "state": "Georgia" }, { "city": "Rockville", "state": "Maryland" }, { "city": "Norfolk", "state": "Nebraska" } ], "official_url": "https://clinicaltrials.gov/study/NCT03658629" } ] }